Anti-NMDA receptor encephalitis epidemiology and demographics: Difference between revisions
Created page with "__NOTOC__ {{Anti-NMDA receptor encephalitis}} {{CMG}} ==Overview== ==Epidemiology and Demographics== ==References== {{Reflist|2}} Category:Needs content Category:Rheu..." |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Anti-NMDA receptor encephalitis}} | {{Anti-NMDA receptor encephalitis}} | ||
{{CMG}} | {{CMG}}; AE {{DMakkar}} | ||
==Overview== | ==Overview== |
Revision as of 00:38, 20 January 2023
Anti-NMDA receptor encephalitis Microchapters |
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Anti-NMDA receptor encephalitis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis epidemiology and demographics |
FDA on Anti-NMDA receptor encephalitis epidemiology and demographics |
CDC on Anti-NMDA receptor encephalitis epidemiology and demographics |
Anti-NMDA receptor encephalitis epidemiology and demographics in the news |
Blogs on Anti-NMDA receptor encephalitis epidemiology and demographics |
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
Risk calculators and risk factors for Anti-NMDA receptor encephalitis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; AE Dheeraj Makkar, M.D.[2]